Феринжект

Феринжект (Ferric Carboxymaltose) is an intravenous iron replacement therapy used to treat iron deficiency when oral supplements are ineffective. It replenishes iron stores efficiently for patients with anemia or iron deficiency. This product is administered by healthcare professionals in clinical settings.

Ferric Carboxymaltose is used to address iron deficiency anemia in adults and children when dietary sources or oral supplements fail to restore iron levels. It is particularly effective for patients with chronic kidney disease, gastrointestinal disorders, or heavy menstrual bleeding. The therapy helps improve energy levels and overall well-being by correcting low iron stores.

Patients receiving Ferric Carboxymaltose often report improved energy and reduced fatigue as iron levels normalize. Some may experience temporary warmth or flushing during administration, which typically resolves quickly. The therapy supports red blood cell production, aiding in the recovery from anemia-related symptoms.

Ferric Carboxymaltose should only be administered by trained healthcare providers in a clinical setting. Patients with a history of allergic reactions to iron products should inform their provider before treatment. Monitoring for signs of hypersensitivity, such as low blood pressure or rash, is recommended during and after administration.

Ferric Carboxymaltose may interact with certain medications, including oral iron supplements and phosphate binders, which can reduce its absorption. Alcohol and other substances affecting iron metabolism should be used cautiously. Always disclose all medications and supplements to your healthcare provider before starting this therapy.